The combination of CUDC-907 and gilteritinib shows promising in vitro and in vivo antileukemic activity against FLT3-ITD AML

Cancer Statistics, 2021

(2021) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Antileukemic activity and mechanism of action of the novel PI3K and histone deacetylase dual inhibitor CUDC-907 in acute myeloid leukemia

(2019) Xinyu Li et al.   HAEMATOLOGICA

Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-mutated Acute Myeloid Leukemia

(2019) Jun Ma et al.   CLINICAL CANCER RESEARCH

Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML

(2019) Alexander E. Perl et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting PI3K, mTOR, ERK, and Bcl-2 signaling network shows superior antileukemic activity against AML ex vivo

(2018) Yongwei Su et al.   BIOCHEMICAL PHARMACOLOGY

Glutaminolysis is a metabolic dependency in FLT3ITDacute myeloid leukemia unmasked by FLT3 tyrosine kinase inhibition

(2018) Paolo Gallipoli et al.   BLOOD

Cancer statistics, 2018

(2018) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

ASP2215 in the treatment of relapsed/refractory acute myeloid leukemia with FLT3 mutation: background and design of the ADMIRAL trial

(2018) Claudia M Gorcea et al.   Future Oncology

The Role for Myc in Coordinating Glycolysis, Oxidative Phosphorylation, Glutaminolysis, and Fatty Acid Metabolism in Normal and Neoplastic Tissues

(2018) Eric S. Goetzman et al.   Frontiers in Endocrinology

Inhibition of XPO1 enhances cell death induced by ABT-199 in acute myeloid leukaemia via Mcl-1

(2018) Daniel A. Luedtke et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Pharmacometabolomics Reveals Irinotecan Mechanism of Action in Cancer Patients

(2018) Xun Bao et al.   JOURNAL OF CLINICAL PHARMACOLOGY

CUDC-907 in relapsed/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase I trial

(2017) Yasuhiro Oki et al.   HAEMATOLOGICA

Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study

(2017) Alexander E Perl et al.   LANCET ONCOLOGY

FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions

(2017) Maria Larrosa-Garcia et al.   MOLECULAR CANCER THERAPEUTICS

FLT3-ITD induces expression of Pim kinases through STAT5 to confer resistance to the PI3K/Akt pathway inhibitors on leukemic cells by enhancing the mTORC1/Mcl-1 pathway

(2017) Keigo Okada et al.   Oncotarget

CUDC-907 in relapsed/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase I trial

(2017) Yasuhiro Oki et al.   HAEMATOLOGICA

Mechanisms responsible for the synergistic antileukemic interactions between ATR inhibition and cytarabine in acute myeloid leukemia cells

(2017) Jun Ma et al.   Scientific Reports

Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor

(2016) Lauren Y. Lee et al.   BLOOD

FGF2 from Marrow Microenvironment Promotes Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia

(2016) Elie Traer et al.   CANCER RESEARCH

Molecular Pathways: AXL, a Membrane Receptor Mediator of Resistance to Therapy

(2016) M. Scaltriti et al.   CLINICAL CANCER RESEARCH

Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial

(2016) Anas Younes et al.   LANCET ONCOLOGY

MYC and metabolism on the path to cancer

(2015) Annie L. Hsieh et al.   SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY

MYC, Metabolism, and Cancer

(2015) Z. E. Stine et al.   Cancer Discovery

Acute myeloid leukemia cells harboring MLL fusion genes or with the acute promyelocytic leukemia phenotype are sensitive to the Bcl-2-selective inhibitor ABT-199

(2014) X Niu et al.   LEUKEMIA

Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma

(2013) I. Ben-Batalla et al.   BLOOD

Bone marrow stroma-mediated resistance to FLT3 inhibitors in FLT3-ITD AML is mediated by persistent activation of extracellular regulated kinase

(2013) Xiaochuan Yang et al.   BRITISH JOURNAL OF HAEMATOLOGY

Panobinostat Enhances Cytarabine and Daunorubicin Sensitivities in AML Cells through Suppressing the Expression of BRCA1, CHK1, and Rad51

(2013) Chengzhi Xie et al.   PLoS One

How I treat pediatric acute myeloid leukemia

(2012) J. E. Rubnitz   BLOOD

Axl-dependent signalling: a clinical update

(2011) Vyacheslav A. Korshunov   CLINICAL SCIENCE

Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway

(2011) A M Martelli et al.   LEUKEMIA

Mechanisms of Synergistic Antileukemic Interactions between Valproic Acid and Cytarabine in Pediatric Acute Myeloid Leukemia

(2010) C. Xie et al.   CLINICAL CANCER RESEARCH

Discovery of 5-Chloro-N2-[(1S)-1-(5-fluoropyrimidin-2-yl)ethyl]-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (AZD1480) as a Novel Inhibitor of the Jak/Stat Pathway

(2010) Stephanos Ioannidis et al.   JOURNAL OF MEDICINAL CHEMISTRY

Ubiquitin conjugase UBCH8 targets active FMS-like tyrosine kinase 3 for proteasomal degradation

(2010) M Buchwald et al.   LEUKEMIA

FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation

(2009) G. Yoshimoto et al.   BLOOD

Bim Upregulation by Histone Deacetylase Inhibitors Mediates Interactions with the Bcl-2 Antagonist ABT-737: Evidence for Distinct Roles for Bcl-2, Bcl-xL, and Mcl-1

(2009) S. Chen et al.   MOLECULAR AND CELLULAR BIOLOGY

c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism

(2009) Ping Gao et al.   NATURE

MS-275, a novel histone deacetylase inhibitor with selectivity against HDAC1, induces degradation of FLT3 via inhibition of chaperone function of heat shock protein 90 in AML cells

(2008) Chie Nishioka et al.   LEUKEMIA RESEARCH

Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction

(2008) D. R. Wise et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA